Presbyopia

LENZ Therapeutics licenses FDA-approved presbyopia drop to Everest Medicines for Greater China; NDA under review by NMPA with approval anticipated in Q1 2027

The study, led by researchers at Keio University School of Medicine, measured near add power in 6258 patients aged 40 to 79.

Data from a recent trial of the OmniVu Lens System was presented at ASCRS 2026, featuring positive and sustained vision endpoints.

The formulation combines 2 pharmacologic agents: carbachol, a direct-acting cholinergic agonist, and brimonidine tartrate, an alpha-2 adrenergic receptor agonist.

The FDA has assigned a PDUFA goal date of October 17, 2026.

Cataract surgeons discuss their comprehensive approach to IOL counseling

Tenpoint Therapeutics’ YUVEZZI, expected in the US in Q2 2026, is the first fixed-dose combination drop designed to improve near vision via pupil modulation with once-daily dosing.

A study reveals that low-dose pilocarpine effectively reduces pupil size in presbyopic eyes with minimal impact on lens thickness and accommodation.

Formerly, the EDOF technology was specifically limited to intraocular lenses.

This is the first submission for approval under the exclusive license and commercialization agreement for South Korea that was signed between LENZ and Lotus.

The topical ophthalmic solution is preservative-free and includes dual lubricants—hyaluronic acid and hydroxypropyl methylcellulose—for patient comfort.

How pupil modulation and pharmacologic targeting shape near vision outcomes.

Vizz is the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults

Innovation, adaptability, and clear communication are key to managing outcomes.

Advances address a need for the growing populace with age-related near vision loss.

Vizz (Lenz Therapeutics) is the first and only aceclidine-based eye drop for presbyopia and is also the first daily solution to correct vision for up to 10 hours.

LENZ Therapeutics previously licensed Greater China rights to CORXEL for the development and commercialization of LNZ100 in April 2022.

Phentolamine Ophthalmic Solution 0.75% is a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, administered as an eye drop for the treatment of presbyopia.

The FDA has set a Prescription Drug User Fee Act (PDUFA) date of January 28, 2026.

Alex Hacopian, MD, highlights how a recent ambispective study demonstrated strong visual acuity outcomes and patient satisfaction following bilateral implantation of an advanced presbyopia-correcting intraocular lens.

Updated guidelines characterize IOLs by functional performance over optical design.

Personalizing treatment options and setting realistic expectations are crucial.